Clinical Trial: Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502508) titled 'Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy' on March 26.

Brief Summary: This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: icovamenib 100 mg

icovamenib 100 mg

DRUG: Placebo

Matching placebo

Recruitment Status: RECRUITING

Sponsor: Biomea Fusion Inc.

Pu...